Lawyers for Ovarian Cancer Victims Urge NO Vote on J&J’s Latest Bankruptcy Plan
Lawyers representing ovarian cancer victims are urging a NO vote on Johnson & Johnson's (NYSE:JNJ) latest $6.5 billion bankruptcy settlement plan. They claim J&J is misleading potential claimants and attempting to secure approvals from individuals without documented ovarian cancer diagnoses. The attorneys argue this strategy could reduce payments to legitimate victims who have incurred losses of $500,000 or more.
The deadline for voting on the bankruptcy proposal is July 26, 2024. Opponents of the plan note that approval would eliminate rights to a jury trial for current and future victims. Since 2016, juries have awarded over $5.4 billion in damages to ovarian cancer claimants, although this amount has been reduced in subsequent court proceedings.
Gli avvocati che rappresentano le vittime di cancro ovarico fanno appello a un NO per il piano di concordato fallimentare da 6,5 miliardi di dollari di Johnson & Johnson (NYSE:JNJ). Sostengono che J&J stia ingannando potenziali richiedenti e tentando di ottenere approvazioni da individui senza diagnosi documentate di cancro ovarico. Gli avvocati sostengono che questa strategia potrebbe ridurre i pagamenti alle vittime legittime che hanno subito perdite di 500.000 dollari o più.
La scadenza per votare sulla proposta di fallimento è il 26 luglio 2024. Gli oppositori del piano notano che l'approvazione eliminerebbe i diritti a un processo con giuria per le vittime attuali e future. Dal 2016, le giurie hanno assegnato oltre 5,4 miliardi di dollari in risarcimenti ai richiedenti per cancro ovarico, anche se questa somma è stata ridotta in procedimenti giudiziari successivi.
Los abogados que representan a las víctimas de cáncer de ovario están pidiendo un NO al último plan de liquidación por bancarrota de 6.5 mil millones de dólares de Johnson & Johnson (NYSE:JNJ). Afirman que J&J está engañando a posibles reclamantes y tratando de obtener aprobaciones de individuos sin diagnósticos documentados de cáncer de ovario. Los abogados argumentan que esta estrategia podría reducir los pagos a las víctimas legítimas que han sufrido pérdidas de 500,000 dólares o más.
La fecha límite para votar sobre la propuesta de bancarrota es el 26 de julio de 2024. Los opositores al plan señalan que la aprobación eliminaría los derechos a un juicio por jurado para las víctimas actuales y futuras. Desde 2016, los jurados han otorgado más de 5.4 mil millones de dólares en daños a los reclamantes de cáncer de ovario, aunque esta cantidad se ha reducido en procesos judiciales posteriores.
난소암 피해자를 대리하는 변호사들은 Johnson & Johnson(NYSE:JNJ)의 최신 65억 달러의 파산 합의안에 대해 반대 투표를 촉구하고 있습니다. 그들은 J&J가 잠재적인 청구인들을 오도하고 있으며, 문서화된 난소암 진단이 없는 개인으로부터 승인을 얻으려 하고 있다고 주장합니다. 변호사들은 이 전략이 50만 달러 이상의 손실을 입은 합법적인 피해자에게 지급되는 금액을 줄일 수 있다고 주장합니다.
파산 제안에 대한 투표 마감일은 2024년 7월 26일입니다. 반대론자들은 승인이 현재 및 미래의 피해자에게 배심원 재판의 권리를 제거할 것이라고 지적합니다. 2016년 이후 배심원들은 난소암 청구인에게 54억 달러 이상의 손해 배상을 지급했지만, 이후 법원 절차에서 이 금액은 줄어든 바 있습니다.
Les avocats représentant les victimes du cancer de l'ovaire exhortent à un vote NON sur le dernier plan de règlement de faillite de 6,5 milliards de dollars de Johnson & Johnson (NYSE:JNJ). Ils affirment que J&J induit en erreur les demandeurs potentiels et tente d'obtenir des approbations d'individus sans diagnostics documentés de cancer de l'ovaire. Les avocats soutiennent que cette stratégie pourrait réduire les paiements aux victimes légitimes ayant subi des pertes de 500 000 dollars ou plus.
La date limite pour voter sur la proposition de faillite est le 26 juillet 2024. Les opposants au plan notent que l'approbation éliminerait les droits à un procès par jury pour les victimes actuelles et futures. Depuis 2016, les jurys ont accordé plus de 5,4 milliards de dollars en dommages-intérêts aux demandeurs de cancer de l'ovaire, bien que ce montant ait été réduit lors de procédures judiciaires subséquentes.
Anwälte, die die Opfer von Eierstockkrebs vertreten, fordern eine NEIN-Stimme zu Johnson & Johnsons (NYSE:JNJ) neuestem 6,5 Milliarden Dollar Insolvenzvergleichsplan. Sie behaupten, dass J&J potenzielle Anspruchsteller irreführt und versucht, Genehmigungen von Personen zu sichern, die keine dokumentierten Eierstockkrebsdiagnosen haben. Die Anwälte argumentieren, dass diese Strategie die Zahlungen an legitime Opfer, die Verluste von 500.000 Dollar oder mehr erlitten haben, verringern könnte.
Die Frist für die Abstimmung über den Insolvenzvorschlag ist der 26. Juli 2024. Die Gegner des Plans weisen darauf hin, dass eine Genehmigung die Rechte auf einen Geschworenenprozess für aktuelle und zukünftige Opfer beseitigen würde. Seit 2016 haben Geschworene über 5,4 Milliarden Dollar an Schadenersatz an Kläger für Eierstockkrebs zugesprochen, obwohl dieser Betrag in nachfolgenden Gerichtsverfahren reduziert wurde.
- None.
- J&J faces opposition to its $6.5 billion bankruptcy settlement plan for talc-related claims
- Attorneys claim J&J is misleading potential claimants to secure approvals
- Approval of the bankruptcy plan could reduce payments to legitimate ovarian cancer victims
- The proposed settlement would eliminate rights to jury trials for current and future victims
- J&J's bankruptcy attempts have been denied twice before for being filed in bad faith
- The company's strategy may delay resolution of cases and avoid trials
Beasley Allen, Levin Papantonio, and coalition of law firms cite misleading efforts to secure approval
“We believe there is an ongoing effort to attract approvals for J&J’s third attempt at bankruptcy from those without a documented and diagnosed claim of ovarian cancer,” says Andy Birchfield of the Beasley Allen Law Firm.
“While individuals may have a gynecological illness or other medical condition, we don’t believe those votes should be used as part of a bankruptcy effort to coercively resolve ovarian cancer claims linked to Johnson & Johnson’s baby powder. Other claims may involve a serious condition, but we fear they are only being used to stuff the ballot box.”
Under a pre-packaged bankruptcy,
Birchfield and attorneys from more than 50 law firms opposing J&J’s voting scheme believe that the solicitation for “yes” votes is being used to create a false basis for a bankruptcy that could reduce payments to their clients, who have incurred individual losses and expenses of
“J&J is aware that the thousands of fantasy cases they are submitting to bankruptcy make it almost impossible for actual injured clients to recover,” says Mike Papantonio of Levin Papantonio.
Employing an at-times desperate strategy, J&J has attacked its former customers who have filed lawsuits, labeling them “nameless” and “faceless.” “This is a profoundly insulting statement to make about the very customers who trusted the company,” says Birchfield. “Thousands of women – mothers, sisters, daughters, aunts & cousins, whose lives have been upended by ovarian cancer linked to J&J’s talc products.”
Video: Victims Speak Out
Scores of women have described their pain in videos as they have battled ovarian cancer and opposed the bankruptcy plan on principle.
“These are real people who have suffered solely because of the deceit of Johnson & Johnson,” says Richard Golomb of Golomb Legal. “Under J&J’s plan, there is no basis to know how much a client would be paid or when, but it’s logical that accepting an extraordinarily large number of claims would reduce the benefit available to all.
“A few thousand dollars is not justifiable for an individual with a legitimate and longstanding medical diagnosis of ovarian cancer, but that’s what the math of this proposal demonstrates.”
The deadline for voting to approve or decline the bankruptcy proposal is 5 p.m. ET on July 26, 2024.
Attorneys opposing the J&J plan also note that approval would take away all rights to a jury trial for current and future ovarian cancer victims. Since 2016, juries have awarded collectively more than
“We welcome any individuals and their attorneys to file claims, with the required medical records and pathology reports, in the ongoing multidistrict litigation for ovarian cancer cases,” says Michelle Parfitt, co-lead counsel of the plaintiffs’ committee over more than 50,000 plaintiffs whose claims were previously consolidated in multidistrict litigation (MDL) in federal court. “The MDL, and civil courts in general, still provide the most fair and efficient means of trying and resolving these cases, with the first bellwether trial scheduled for December.”
“Those trials have been delayed solely due to J&J’s gamesmanship, desire to avoid trials, and repeated and unsuccessful attempts to claim bankruptcy for a company valued at nearly
View source version on businesswire.com: https://www.businesswire.com/news/home/20240722309512/en/
Mike Androvett
800-559-4534
mike@androvett.com
Source: Beasley Allen Law Firm
FAQ
What is the deadline for voting on Johnson & Johnson's (JNJ) bankruptcy proposal?
How much is Johnson & Johnson's (JNJ) proposed bankruptcy settlement for talc-related claims?
Why are lawyers urging a NO vote on Johnson & Johnson's (JNJ) bankruptcy plan?